THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER

Prostate cancer initially responds to androgen-deprivation therapy, but most patients eventually develop a castration-resistant form of disease. Enzalutamid is the superselective inhibitor of the androgen receptor (AR), which blocks several stages of the AR signal path. The drug showed significant e...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: A. A. GRITSKEVICH, S. V. MISHUGIN, I. G. RUSAKOV
Natura: Artigo
Lingua:Russo
Pubblicazione: Remedium Group LLC 2017-06-01
Serie:Медицинский совет
Soggetti:
metastatic cancer
enzalutamide
abiraterone acetate
castration resistance
Accesso online:https://www.med-sovet.pro/jour/article/view/1894
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi